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Background: Epidemiological studies suggested a positive relationship between
breast density and risk of breast cancer. One of the common hormonal disorders
in women’s reproductive age is polycystic ovarian syndrome (PCOS) and the results
from the studies about the risk of breast cancer among PCOS patients are equivocal.
Objective: The objective was to evaluate the breast density in PCOS patients compared
with the control group.
Materials and Methods: In this case-control study, the PCOS patients who were older
than 40 years and were referred to infertility or gynecology outpatient clinic of Arash
women’s hospital between 2015 and 2017 were selected as the case group. Control
group was selected from healthy women who attended the same hospital and were
older than 40 years. By digital mammography, breast density was classified according
to the Breast Imaging Reporting and Data System (BIRADS) of the American College
of Radiology and it was graded by one expert radiologist.
Results: Final analysis in 68 cases and controls showed statistically significant
differences between breast densities in PCOS patients compared to the control
(p = 0.03), and when the analysis was conducted by considering the category of
age, the control group who were younger than 45 years had higher breast density
compared with PCOS patient. Multivariate logistic regression analyses manifested a
statistically significant adverse association between body mass index (OR = 0.87, 95%
CI: 0.79–0.95), vitamin D intake (OR = 0.35, 95% CI: 0.16–0.81), and breast density.
Conclusion: Our data suggested that the PCOS patients had lower breast density
compared with normal population. However, in multivariate analysis, considering other
confounders, this association was not confirmed.
Key words: Breast density, Mammographic, Polycystic ovarian syndrome, Breast
cancer.
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1. Introduction
Breast density is a measure used to describe
women’s mammogram by the amount of fibrous
and glandular tissue. The issue of breast density
and its relation to breast cancer has been a hot
topic over the last several years. A meta-analysis
study in 2006 manifested the strong association
between breast density and breast cancer (Relative
risk: 4.64, 95%CI: 3.63–5.91) for the high density
compared with the low dense category (1). A
recent biological study in 2018 revealed in dense
breast tissue the transition of breast epithelial cells
from normal to malignant cells is more frequent
compared with the non-dense tissue (2). Therefore,
the amount of mammographic density is one of
the risk factors for breast cancer (3). Researchers
investigated the effects of different variables such
as age, reproductive and hormonal factors, body
size, and anthropometric characteristics on breast
density (4–7). Epidemiological studies reported
the relationship between breast density and
hormonal factors associated with infertility such as
anovulation or other forms of luteal deficiency (6, 8).
One of the common hormonal disorders in women’s
reproductive age is polycystic ovarian syndrome
(PCOS), and using different criteria, the prevalence
in different geographic regions of Iran was reported
to be 7.1–14.6% (9). The results from the studies
about the risk of breast cancer among PCOS
patients are equivocal (10–13). Recent finding from
a systematic review and meta-analysis in 2014 did
not manifest the relationship between ovarian and
breast cancer with PCOS in all ages (14). However, a
nationwide population-based retrospective cohort
study concluded the possible increasing the risk
of breast cancer in PCOS patients (15). A study in
Iran was conducted to evaluate the prevalence of
PCOS in premenopausal breast cancer patients and
they found no relation between PCOS and breast
cancer (16). Since the prevalence of the risk factors
of cancer is high in Iran, and the trend is growing
up (17) and breast cancer patients with advanced
stages of disease are relatively younger (about
10 yr) than their western counterpart (18), assessing
the risk of breast cancer in probable high-risk
population is necessary in order to prevention and
early detection of this disease.
Therefore, the objective of this study was to
compare the breast density as a known risk
factor for breast cancer in patients with PCOS in
comparison with a control group in Iranian women
population.
2. Materials and Methods
This case-control study is conducted on 136
women who attended Arash women’s hospital
in Tehran, Iran, during 2015–2017. Case group
was selected from women referred to infertility
or gynecology outpatient clinic and PCOS was
confirmed in them.
PCOS was diagnosed according to the
Rotterdam criteria (at least two of the following
criteria): oligo/amenorrhea, clinical or biochemical
hyperandrogenism, and polycystic ovaries (PCO)
on ultrasonography (10 or more peripheral follicular
cysts at most 8 mm in diameter in one plane along
with increased central ovarian stroma) (19). Control
group was selected from women who attended
the same hospital, and sonographic and clinical
evaluation revealed that they had normal ovaries
and PCOS was not diagnosed in them.
The exclusion criteria for both the groups were:
Cushing syndrome, late-onset adrenal hyperplasia,
androgen-producing neoplasm, hyperprolactine-
mia, previous history of breast cancer or breast
surgery, renal failure, and usage of estrogen, pro-
gesterone, and androgen. The age of all parti-
cipants was more than 40 yr and they were
in premenopausal status. Breast screening was
performed by digital mammography in two stan-
dard mediolateral-oblique and craniocaudal views
for all normal-risk patients 40 yr of age or more
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as a routine in Arash woman’s hospital. Breast
Imaging Reporting and Data System (BIRADS)
that was established by the American College
of Radiology (ACR) was used to classify breast
density. Four BIRADS categories for breast density
was identified by an expert radiologist. BIRADS
1 and 2 were considered as low density and
3 and 4 as high density. The trained physician
gathered individual information about age, age
of menarche, weight, height, waist and hip
circumference, menstrual pattern, parity, previous
history of abortion, hormone therapy, vitamin D and
calcium consumption, daily sun exposure (≤30 and
>30 min), and family history of breast surgery by
in-person interviews. Age was categorized into two
groups (<45 and ≥45 yr). Body mass index (BMI)
is defined as weight divided by height squared
(kg/m2), and it was classified according to the
WHO classification (<18.5, 18.5–24.99, 25-29.99,
≥30). The waist and hip circumferences of each
participant were used to construct a waist-hip ratio
(WHR cm/cm). Both Active and passive smoking
was considered as smoking status. Having more
than 10 minutes of any activity per day that led to
increased heartbeat and breathing was defined as
physical activity.
2.1. Sample size
Based on the results of previous study in our
population (20), the prevalence of high density in
the control group was about 40%. In order to detect
25% difference in the prevalence of high-density
breast between two groups, we calculated that 70
people will be required in each group with the
power of 80% and α = 0.05 by using the Epi Info
website (www.cdc.gov/epiinfo/).
2.2. Ethical consideration
The present study was approved by the
ethics committee of Tehran University of Medical
Sciences (code: IR.TUMS.REC.1394.254) and an
informed consent was obtained from all individual
participants included in the study.
2.3. Statistical analysis
Statistical Package for the Social Sciences
software (SPSS, version 18.0, Chicago, IL, USA)
was used for statistical analysis. Categorical and
continuous variables are expressed as number (%)
and mean ± standard deviation, respectively. The
differences between variables were tested with
Pearson chi-square tests and independent t-test.
Multivariate logistic regression analysis was used
to examine the association between breast density
(low/high) as the dependent variable and other
independent variables. In the multivariate model,
variables were entered to the model based on our
previous knowledge and p < 0.2, whereas p = 0.1
was the threshold for a variable to stay in the model.
Results are presented as odds ratio (OR) with 95%
confidence intervals (CI). P-value less than 0.05 was
considered as statistically significant and all tests
were two-sided.
3. Results
Final analysis was performed with 68 samples in
each group. Table I shows the total characteristics
of the study sample. PCOS patients had a
significantly higher BMI, WHR, and hormone therapy
as expected (p < 0.05). Meanwhile, PCOS patients
were in more exposure to cigarette smoke (active
or passive), had more physical activity and calcium
intake than the other group.
The results revealed statistically significant
differences between breast densities in PCOS
patients compared to the control (p = 0.03). When
the analysis was conducted by considering the
category of age the control group who were
younger than 45 yr old had higher breast density
compared with PCOS patient (Table II). Whereas,
no association was found between the two groups
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with ≥45 yr old. Table III shows the comparison of
all variables between low- and high-density group.
Overall, statistically significant difference was
observed in BMI, vitamin D intake, and family history
of breast surgery between low- and high-density
group. The results of multivariate logistic regression
analysis considering the following covariates: group
(PCOS/control), age (yr), BMI (kg/m2), WHR, vitamin
D intake (no/yes), physical activity, and positive
Table I. Total characteristics of case (PCOS) and control groups
Variables PCOS (n = 68) Control (n = 68) P-value
Age (yrs)∗ 45.24 ± 4.07 45.73 ± 4.22 0.50
BMI (kg/m2) ∗ 29.42 ± 6.67 27.58 ± 4.41 0.06
WHR∗ 0.88 ± 0.09 0.83 ± 0.07 0.001
Parity (n)∗ 2.42 ± 1.09 2.28 ± 1.02 0.48
Age at first pregnancy (yr)∗ 23.49 ± 6.66 21.94 ± 5.16 0.18
Age of menarche (yr)∗ 13.71 ± 1.80 13.63 ± 2.45 0.84
The family history of breast surgery∗∗ 17 (25) 10 (14.7) 0.20
Exposure to cigarette smoke∗∗ 20 (29.4) 10 (14.7) 0.06
Physical activity∗∗ 53 (77.9) 29 (42.6) <0.001
History of breastfeeding∗∗ 52 (76.5) 54 (79.4) 0.84
Daily sun exposure more than 30 min∗∗ 4 (5.9) 15 (22.1) 0.01
History of abortion∗∗ 22 (32.4) 16 (23.5) 0.34
Vitamin D intake∗∗ 24 (35.3) 18 (26.5) 0.35
Calcium intake∗∗ 64 (94.1) 51 (75) 0.004















∗Data expressed as mean ± SD; ∗∗ Data expressed as number (%)
P-value refers to t-test in comparison of continues variables and Chi-square test was conducted between categorical variables
PCOS: Polycystic ovarian syndrome; BMI: Body mass index; WHR: Waist-hip ratio
Table II. Comparison of breast density in two groups considering age category
Age category Group Low density High density P-value
<45 yr PCOS 26 (63.4) 15 (36.6)
Control 14 (37.8) 23 (62.2)
0.04
≥45 yr PCOS 12 (44.4) 15 (55.6)
Control 16 (51.6) 15 (48.4)
0.61
Data expressed as n (%); Chi-squared test
family history of breast surgery (no/yes) were
manifested in Table IV. The adjusted OR illustrated a
statistically significant adverse association between
BMI (OR = 0.87, 95% CI: 0.79–0.95) and vitamin D
intake (OR = 0.35, 95% CI: 0.16-0.81) with breast
density. In addition, the family history of breast
surgery (OR = 2.54, 95% CI: 0.96–6.67) had a
positive association with breast density with a
borderline p = 0.06.
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Table III. Multivariate logistic regression analysis by considering the breast density (low/high) as the dependent variable
Covariates OR 95% CI P-value
BMI 0.87 0.79–0.95 0.002
Vitamin D intake 0.35 0.16–0.81 0.01
The family history of breast surgery 2.54 0.96–6.67 0.06
Variables age, group (PCOS/control), BMI, WHR, vitamin D intake, physical activity, and positive family history of breast surgery
were entered to the model
OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; PCOS: Polycystic ovarian syndrome
Table IV. Comparison of variables two groups of the low- and high-density of breast




















Age of Menarche∗∗ 13.56 ± 2.49 13.78 ± 1.75 0.55
Age at first delivery∗∗ 23.26 ± 6.67 22.23 ± 5.27 0.39
WHR∗∗ 0.87 ± 0.07 0.84 ± 0.09 0.07
Regular menstruation∗ 35 (51.5) 33 (48.5) 0.86
Vitamin D consumption∗ 14 (20.6) 28 (41.2) 0.02
Calcium consumption∗ 56 (82.4) 59 (86.8) 0.64
The positive family history of breast surgery∗ 8 (11.8) 19 (27.9) 0.03
Daily sun exposure more than 30 min∗ 10 (14.7) 9 (13.2) 1
Exposure to cigarette smoke∗ 15 (22.1) 15 (22.1) 1
Physical activity∗ 45 (66.2) 37 (54.4) 0.22
History of breast feeding∗ 50 (73.5) 56 (82.4) 0.30
History of abortion∗ 21 (30.9) 17 (25) 0.57
∗Data expressed as number (%);
∗∗Data expressed as mean ± SD
P-value refers to t-test in comparison of continues variables and Chi-square test was conducted between categorical variables
BMI: Body mass index; WHR: Waist-hip ratio
4. Discussion
In the present study, we evaluated the breast
density as a well-known risk factor of breast cancer
in PCOS patients compared with the normal group
in Iranian women. We reported the statistically
significant difference in the breast density between
PCOS and control group (Table I). As we mentioned
in Table I, 23.5% of PCOS patients belong to the
lower category of ACR breast density in comparison
with 5.9% in control group, and ACR category of 3
was higher in control group in comparison with the
case group (44.1% vs 30.9%). Since the previous
epidemiological study reported high breast density
is a risk factor of breast cancer, and our finding didn’t
confirm the high breast density in PCOS patients,
our data suggest that PCOS patients are not at
an increased risk of breast cancer due to breast
density. Therefore, it seems that other mechanisms
except breast density should be investigated in the
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PCOS population in order to detect the relationship
between the breast cancer and PCOS.
Our results support several investigations that
show women with PCOS are not at increased
risk of breast cancer (10–12, 14). Similar to the
present study, the association between PCOS and
breast cancer risk in a meta-analysis was estimated
at 0.87 (95% CI, 0.44–1.31). Although the finding
of the study is not statistically significant, they
created a hypothesis about the protective effect of
PCOS in breast cancer risk (21). The anovulatory
and irregular menstrual cycle is common in
PCOS patients. Our finding is consistent with
the hypothesis which reported that the reduced
exposure to ovulatory menstrual cycles period
is a protective effect against breast cancer (22).
Two studies displayed results in contradiction with
the present study. They reported the possible
association between PCOS and breast cancer
(13, 23). Kim et al. reported that PCOS and
PCOS-related symptoms may play a role in the
development of premenopausal breast cancer
(13).
In this study, we found that the cigarette smoke
exposure in PCOS patients was higher than in
the control group with a borderline p-value (0.06),
and the breast density in PCOS group was lower
than the control group. This result supported
previous evidence about the relationship between
smoking and breast density that reported the
lower measure of breast density in a current
smoker than non-smokers (24–26). Since the
exposure to estrogen has been associated with
breast density positively, these protective effects
of smoking might be due to the anti-estrogenic
effect of cigarette smoking (27). Therefore, higher
exposure to cigarette smoke in PCOS patients
may cause decreased breast density in this group.
As we found in multivariate analysis, BMI is
inversely associated with breast density and it
was confirmed by another study (5). Because
one investigation has shown metabolic syndrome
and its components such as insulin resistance
were related to the dense breast (23) and PCOS
disease is associated with a variety of clinical
and laboratory findings such as hyperandrogenism
and insulin resistance, we expected to observe
the dense breast in PCOS patients. However,
the present results have not confirmed this
opinion. Because we did not have access to the
hormonal profiles such as insulin resistance in
PCOS patients, we are not able to investigate
this issue.
Considering our result, vitamin D intake has a
negative relation with breast density (OR = 0.35,
95% CI: 0.16–0.81). This issue was confirmed
by the other investigations which suggested that
the dietary vitamin D could reduce the risk of
breast cancer (28, 29). Ziv et al. revealed that
women with higher breast density were more likely
to have first-degree relatives with breast cancer
(30), and this study showed that women who
had positive family history of any breast surgery
are at increased risk of high-density breast with
OR equal to 2.54 (95% CI: 0.96–6.67) and a
borderline p-value (0.06). Finally, PCOS patients
of the present study had more physical activity
compared with the control group. Epidemiological
studies manifested that the increased physical
activity declines the mammographic dense area
(31, 32). Further studies are needed to confirm this
association in premenopausal women.
5. Conclusion
The low breast density in PCOS samples of
this study may relate to hormonal disorders
and anovulation cycles, cigarette smoke,
BMI, vitamin D intake, and physical activity.
However, the final analysis did not manifest the
association between groups (PCOS/control) and
breast density considering other independent
variables.
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Our study displayed various advantages. Firstly,
it was the first evaluation of breast density in PCOS
patients in Iranian women population, and based on
our knowledge, we didn’t find any other studies on
this topic. Another advantage of the present study
was that all mammographic density assessment was
performed by one expert radiologist. This study
had some limitations. The first limitation was about
the power of our study and we couldn’t reach
our estimation for sample size calculation (25%
difference between high or low breast densities
between two groups). Since the age of routine
mammography in Iran is 40 yr, only women who
were older than 40 entered the study due to
budget and time limitations. Another limitation was
the lack of information about hormonal profiles
of all participants. It would be better to conduct
further studies by considering the complete
hormonal profiles of the sample population
such as serum follicle-stimulating hormone (FSH),
luteinizing hormone (LH), progesterone, estradiol,
testosterone, and dehydroepiandrosterone sulfate.
This study supported the role of vitamin D in
order to decrease the breast density as a risk
factor of breast cancer. Meanwhile, screening
mammography should be recommended in women
who had a family history of breast disease. It seems
there are not sufficient data about the risk of breast
cancer in PCOS patients and more investigations in
different ages considering all confounding variables
are necessary.
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